PARIS--(BUSINESS WIRE)--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS):
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date |
Total number of shares in the capital |
Total number of voting |
||
| 05/31/2019 | 42,445,669 | 51,241,049 |
About Cellectis
Cellectis is a clinical-stage
biopharmaceutical company focused on developing a new generation of
cancer immunotherapies based on gene-edited T-cells (UCART). By
capitalizing on its 19 years of expertise in gene editing – built on its
flagship TALEN® technology and pioneering electroporation system
PulseAgile – Cellectis uses the power of the immune system to target and
eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is
listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.
